期刊
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
卷 7, 期 4, 页码 341-351出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/EGH.13.18
关键词
adherence; aminosalicylates; biologics; immunomodulators; prevention of relapse; ulcerative colitis
资金
- Abbott (Japan)
- Ajinomoto Pharma
- Asahi Kasei Kuraray Medical
- AstraZeneca Pharmaceuticals
- Janssen Pharmaceuticals
- JIMRO
- Nissin Kyorin Pharmaceutical Co.
- Otsuka Pharma
- Tanabe Mitsubishi Seiyaku
- UCB (Japan)
- UMN Pharma
- Zeria Pharmaceutical
The clinical management of ulcerative colitis (UC) involves first treating the acute symptoms to induce remission, and then successfully maintaining it. Oral 5-aminosalicylic acids are safe and useful for maintaining remission in patients with UC. In terms of adherence, a once-daily form of 5-aminosalicylic acid is superior in maintaining remission as compared with split dosing. Patients at high risk of relapse may be candidates for treatment with thiopurines and/or biologics in the early stages of UC. Calcineurin inhibitors, such as cyclosporine and tacrolimus, are effective for severe, steroid-refractory UC patients. It is suggested that these patients use thiopurines as their maintenance therapy once they achieve remission with calcineurin inhibitors. Recent studies have confirmed that biologics are effective for inducing clinical and endoscopic remission of UC, and thus they may improve long-term prognosis of UC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据